{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:43:19Z","timestamp":1792690999663,"version":"4.5.0"},"reference-count":193,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T00:00:00Z","timestamp":1611360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T00:00:00Z","timestamp":1611360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007496","name":"Biomedical Laboratory Research and Development, VA Office of Research and Development","doi-asserted-by":"publisher","award":["NEUD-004-07F"],"award-info":[{"award-number":["NEUD-004-07F"]}],"id":[{"id":"10.13039\/100007496","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s12035-021-02283-3","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T19:10:33Z","timestamp":1611342633000},"page":"2672-2691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Targeting Insulin Resistance to Treat Cognitive Dysfunction"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9455-2591","authenticated-orcid":false,"given":"Anit","family":"Tyagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5202-8134","authenticated-orcid":false,"given":"Subbiah","family":"Pugazhenthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,23]]},"reference":[{"issue":"4","key":"2283_CR1","doi-asserted-by":"publisher","first-page":"E531","DOI":"10.1152\/ajpendo.00350.2016","volume":"315","author":"M Hersom","year":"2018","unstructured":"Hersom M, Helms HC, Schmalz C, Pedersen TA, Buckley ST, Brodin B (2018) The insulin receptor is expressed and functional in cultured blood-brain barrier endothelial cells but does not mediate insulin entry from blood to brain. Am J Physiol Endocrinol Metab 315(4):E531\u2013E542. https:\/\/doi.org\/10.1152\/ajpendo.00350.2016","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"5656","key":"2283_CR2","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/272827a0","volume":"272","author":"J Havrankova","year":"1978","unstructured":"Havrankova J, Roth J, Brownstein M (1978) Insulin receptors are widely distributed in the central nervous system of the rat. Nature 272(5656):827\u2013829. https:\/\/doi.org\/10.1038\/272827a0","journal-title":"Nature"},{"issue":"1","key":"2283_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.pharmthera.2012.07.006","volume":"136","author":"WA Banks","year":"2012","unstructured":"Banks WA, Owen JB, Erickson MA (2012) Insulin in the brain: there and back again. Pharmacol Ther 136(1):82\u201393. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.07.006","journal-title":"Pharmacol Ther"},{"issue":"40","key":"2283_CR4","doi-asserted-by":"publisher","first-page":"E8478","DOI":"10.1073\/pnas.1710625114","volume":"114","author":"M Konishi","year":"2017","unstructured":"Konishi M, Sakaguchi M, Lockhart SM, Cai W, Li ME, Homan EP, Rask-Madsen C, Kahn CR (2017) Endothelial insulin receptors differentially control insulin signaling kinetics in peripheral tissues and brain of mice. Proc Natl Acad Sci U S A 114(40):E8478\u2013E8487. https:\/\/doi.org\/10.1073\/pnas.1710625114","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"2283_CR5","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1113\/JP276149","volume":"596","author":"EM Rhea","year":"2018","unstructured":"Rhea EM, Rask-Madsen C, Banks WA (2018) Insulin transport across the blood-brain barrier can occur independently of the insulin receptor. J Physiol 596(19):4753\u20134765. https:\/\/doi.org\/10.1113\/JP276149","journal-title":"J Physiol"},{"issue":"8","key":"2283_CR6","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1007\/s00125-017-4285-4","volume":"60","author":"SM Gray","year":"2017","unstructured":"Gray SM, Aylor KW, Barrett EJ (2017) Unravelling the regulation of insulin transport across the brain endothelial cell. Diabetologia 60(8):1512\u20131521. https:\/\/doi.org\/10.1007\/s00125-017-4285-4","journal-title":"Diabetologia"},{"issue":"7","key":"2283_CR7","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1210\/en.2008-0008","volume":"149","author":"A Urayama","year":"2008","unstructured":"Urayama A, Banks WA (2008) Starvation and triglycerides reverse the obesity-induced impairment of insulin transport at the blood-brain barrier. Endocrinology 149(7):3592\u20133597. https:\/\/doi.org\/10.1210\/en.2008-0008","journal-title":"Endocrinology"},{"issue":"10","key":"2283_CR8","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/s0196-9781(97)00238-6","volume":"18","author":"WA Banks","year":"1997","unstructured":"Banks WA, Jaspan JB, Kastin AJ (1997) Effect of diabetes mellitus on the permeability of the blood-brain barrier to insulin. Peptides 18(10):1577\u20131584. https:\/\/doi.org\/10.1016\/s0196-9781(97)00238-6","journal-title":"Peptides"},{"issue":"1","key":"2283_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ar.1092070108","volume":"207","author":"A Dorn","year":"1983","unstructured":"Dorn A, Bernstein HG, Rinne A, Ziegler M, Hahn HJ, Ansorge S (1983) Insulin- and glucagonlike peptides in the brain. Anat Rec 207(1):69\u201377. https:\/\/doi.org\/10.1002\/ar.1092070108","journal-title":"Anat Rec"},{"issue":"2","key":"2283_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0014-5793(84)80266-5","volume":"168","author":"NP Birch","year":"1984","unstructured":"Birch NP, Christie DL, Renwick AG (1984) Proinsulin-like material in mouse foetal brain cell cultures. FEBS Lett 168(2):299\u2013302. https:\/\/doi.org\/10.1016\/0014-5793(84)80266-5","journal-title":"FEBS Lett"},{"issue":"2","key":"2283_CR11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1073\/pnas.90.2.527","volume":"90","author":"L Deltour","year":"1993","unstructured":"Deltour L, Leduque P, Blume N, Madsen O, Dubois P, Jami J, Bucchini D (1993) Differential expression of the two nonallelic proinsulin genes in the developing mouse embryo. Proc Natl Acad Sci U S A 90(2):527\u2013531. https:\/\/doi.org\/10.1073\/pnas.90.2.527","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1\u20132","key":"2283_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0167-0115(93)90335-6","volume":"48","author":"SU Devaskar","year":"1993","unstructured":"Devaskar SU, Singh BS, Carnaghi LR, Rajakumar PA, Giddings SJ (1993) Insulin II gene expression in rat central nervous system. Regul Pept 48(1\u20132):55\u201363. https:\/\/doi.org\/10.1016\/0167-0115(93)90335-6","journal-title":"Regul Pept"},{"issue":"11","key":"2283_CR13","doi-asserted-by":"publisher","first-page":"8445","DOI":"10.1016\/S0021-9258(17)37214-9","volume":"269","author":"SU Devaskar","year":"1994","unstructured":"Devaskar SU, Giddings SJ, Rajakumar PA, Carnaghi LR, Menon RK, Zahm DS (1994) Insulin gene expression and insulin synthesis in mammalian neuronal cells. J Biol Chem 269(11):8445\u20138454","journal-title":"J Biol Chem"},{"issue":"6","key":"2283_CR14","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.cmet.2012.10.019","volume":"16","author":"AE Mehran","year":"2012","unstructured":"Mehran AE, Templeman NM, Brigidi GS, Lim GE, Chu KY, Hu X, Botezelli JD, Asadi A et al (2012) Hyperinsulinemia drives diet-induced obesity independently of brain insulin production. Cell Metab 16(6):723\u2013737. https:\/\/doi.org\/10.1016\/j.cmet.2012.10.019","journal-title":"Cell Metab"},{"issue":"4\u20135","key":"2283_CR15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s007020050068","volume":"105","author":"L Frolich","year":"1998","unstructured":"Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, Muschner D, Thalheimer A et al (1998) Brain insulin and insulin receptors in aging and sporadic Alzheimer\u2019s disease. J Neural Transm (Vienna) 105(4\u20135):423\u2013438. https:\/\/doi.org\/10.1007\/s007020050068","journal-title":"J Neural Transm (Vienna)"},{"issue":"12","key":"2283_CR16","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/emmm.201100177","volume":"3","author":"T Kuwabara","year":"2011","unstructured":"Kuwabara T, Kagalwala MN, Onuma Y, Ito Y, Warashina M, Terashima K, Sanosaka T, Nakashima K et al (2011) Insulin biosynthesis in neuronal progenitors derived from adult hippocampus and the olfactory bulb. EMBO Mol Med 3(12):742\u2013754. https:\/\/doi.org\/10.1002\/emmm.201100177","journal-title":"EMBO Mol Med"},{"issue":"4","key":"2283_CR17","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1523\/JNEUROSCI.4082-13.2014","volume":"34","author":"G Molnar","year":"2014","unstructured":"Molnar G, Farago N, Kocsis AK, Rozsa M, Lovas S, Boldog E, Baldi R, Csajbok E et al (2014) GABAergic neurogliaform cells represent local sources of insulin in the cerebral cortex. J Neurosci 34(4):1133\u20131137. https:\/\/doi.org\/10.1523\/JNEUROSCI.4082-13.2014","journal-title":"J Neurosci"},{"issue":"4","key":"2283_CR18","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/0306-4522(86)90082-5","volume":"17","author":"JM Hill","year":"1986","unstructured":"Hill JM, Lesniak MA, Pert CB, Roth J (1986) Autoradiographic localization of insulin receptors in rat brain: prominence in olfactory and limbic areas. Neuroscience 17(4):1127\u20131138. https:\/\/doi.org\/10.1016\/0306-4522(86)90082-5","journal-title":"Neuroscience"},{"issue":"4","key":"2283_CR19","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1210\/endo-121-4-1562","volume":"121","author":"GA Werther","year":"1987","unstructured":"Werther GA, Hogg A, Oldfield BJ, McKinley MJ, Figdor R, Allen AM, Mendelsohn FA (1987) Localization and characterization of insulin receptors in rat brain and pituitary gland using in vitro autoradiography and computerized densitometry. Endocrinology 121(4):1562\u20131570. https:\/\/doi.org\/10.1210\/endo-121-4-1562","journal-title":"Endocrinology"},{"issue":"6","key":"2283_CR20","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1210\/endo-127-6-3234","volume":"127","author":"JL Marks","year":"1990","unstructured":"Marks JL, Porte D Jr, Stahl WL, Baskin DG (1990) Localization of insulin receptor mRNA in rat brain by in situ hybridization. Endocrinology 127(6):3234\u20133236. https:\/\/doi.org\/10.1210\/endo-127-6-3234","journal-title":"Endocrinology"},{"issue":"1","key":"2283_CR21","doi-asserted-by":"publisher","first-page":"4070","DOI":"10.1038\/s41598-018-22434-2","volume":"8","author":"B Spencer","year":"2018","unstructured":"Spencer B, Rank L, Metcalf J, Desplats P (2018) Identification of insulin receptor splice variant B in neurons by in situ detection in human brain samples. Sci Rep 8(1):4070. https:\/\/doi.org\/10.1038\/s41598-018-22434-2","journal-title":"Sci Rep"},{"key":"2283_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ghir.2019.02.003","volume":"45","author":"L Martinez-Rachadell","year":"2019","unstructured":"Martinez-Rachadell L, Aguilera A, Perez-Domper P, Pignatelli J, Fernandez AM, Torres-Aleman I (2019) Cell-specific expression of insulin\/insulin-like growth factor-I receptor hybrids in the mouse brain. Growth Hormon IGF Res 45:25\u201330. https:\/\/doi.org\/10.1016\/j.ghir.2019.02.003","journal-title":"Growth Hormon IGF Res"},{"issue":"1","key":"2283_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-39191-5","volume":"9","author":"JJ Lochhead","year":"2019","unstructured":"Lochhead JJ, Kellohen KL, Ronaldson PT, Davis TP (2019) Distribution of insulin in trigeminal nerve and brain after intranasal administration. Sci Rep 9(1):2621. https:\/\/doi.org\/10.1038\/s41598-019-39191-5","journal-title":"Sci Rep"},{"issue":"6","key":"2283_CR24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrm3351","volume":"13","author":"D Leto","year":"2012","unstructured":"Leto D, Saltiel AR (2012) Regulation of glucose transport by insulin: traffic control of GLUT4. Nat Rev Mol Cell Biol 13(6):383\u2013396. https:\/\/doi.org\/10.1038\/nrm3351","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2283_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3389\/fendo.2014.00161","volume":"5","author":"E Blazquez","year":"2014","unstructured":"Blazquez E, Velazquez E, Hurtado-Carneiro V, Ruiz-Albusac JM (2014) Insulin in the brain: its pathophysiological implications for states related with central insulin resistance, type 2 diabetes and Alzheimer\u2019s disease. Front Endocrinol (Lausanne) 5:161. https:\/\/doi.org\/10.3389\/fendo.2014.00161","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1\u20133","key":"2283_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejphar.2004.02.041","volume":"490","author":"BS McEwen","year":"2004","unstructured":"McEwen BS, Reagan LP (2004) Glucose transporter expression in the central nervous system: relationship to synaptic function. Eur J Pharmacol 490(1\u20133):13\u201324. https:\/\/doi.org\/10.1016\/j.ejphar.2004.02.041","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"2283_CR27","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/(SICI)1096-9861(19981005)399:4<492::AID-CNE4>3.0.CO;2-X","volume":"399","author":"S El Messari","year":"1998","unstructured":"El Messari S, Leloup C, Quignon M, Brisorgueil MJ, Penicaud L, Arluison M (1998) Immunocytochemical localization of the insulin-responsive glucose transporter 4 (Glut4) in the rat central nervous system. J Comp Neurol 399(4):492\u2013512","journal-title":"J Comp Neurol"},{"issue":"1","key":"2283_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0006-8993(98)00103-6","volume":"797","author":"SJ Vannucci","year":"1998","unstructured":"Vannucci SJ, Koehler-Stec EM, Li K, Reynolds TH, Clark R, Simpson IA (1998) GLUT4 glucose transporter expression in rodent brain: Effect of diabetes. Brain Res 797(1):1\u201311. https:\/\/doi.org\/10.1016\/s0006-8993(98)00103-6","journal-title":"Brain Res"},{"key":"2283_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.brainres.2009.08.005","volume":"1296","author":"CA Grillo","year":"2009","unstructured":"Grillo CA, Piroli GG, Hendry RM, Reagan LP (2009) Insulin-stimulated translocation of GLUT4 to the plasma membrane in rat hippocampus is PI3-kinase dependent. Brain Res 1296:35\u201345. https:\/\/doi.org\/10.1016\/j.brainres.2009.08.005","journal-title":"Brain Res"},{"issue":"3","key":"2283_CR30","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2337\/db16-0917","volume":"66","author":"CM Reno","year":"2017","unstructured":"Reno CM, Puente EC, Sheng Z, Daphna-Iken D, Bree AJ, Routh VH, Kahn BB, Fisher SJ (2017) Brain GLUT4 knockout mice have impaired glucose tolerance, decreased insulin sensitivity, and impaired hypoglycemic counterregulation. Diabetes 66(3):587\u2013597. https:\/\/doi.org\/10.2337\/db16-0917","journal-title":"Diabetes"},{"issue":"5","key":"2283_CR31","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/(SICI)1097-4547(19990901)57:5<693::AID-JNR11>3.0.CO;2-X","volume":"57","author":"J Apelt","year":"1999","unstructured":"Apelt J, Mehlhorn G, Schliebs R (1999) Insulin-sensitive GLUT4 glucose transporters are colocalized with GLUT3-expressing cells and demonstrate a chemically distinct neuron-specific localization in rat brain. J Neurosci Res 57(5):693\u2013705","journal-title":"J Neurosci Res"},{"key":"2283_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2019.113076","volume":"323","author":"EC McNay","year":"2020","unstructured":"McNay EC, Pearson-Leary J (2020) GluT4: A central player in hippocampal memory and brain insulin resistance. Exp Neurol 323:113076. https:\/\/doi.org\/10.1016\/j.expneurol.2019.113076","journal-title":"Exp Neurol"},{"issue":"4","key":"2283_CR33","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1172\/JCI59903","volume":"122","author":"K Talbot","year":"2012","unstructured":"Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR et al (2012) Demonstrated brain insulin resistance in Alzheimer\u2019s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122(4):1316\u20131338. https:\/\/doi.org\/10.1172\/JCI59903","journal-title":"J Clin Invest"},{"issue":"1","key":"2283_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2337\/db16-0861","volume":"66","author":"AM Fernandez","year":"2017","unstructured":"Fernandez AM, Hernandez-Garzon E, Perez-Domper P, Perez-Alvarez A, Mederos S, Matsui T, Santi A, Trueba-Saiz A et al (2017) Insulin regulates astrocytic glucose handling through cooperation with IGF-I. Diabetes 66(1):64\u201374. https:\/\/doi.org\/10.2337\/db16-0861","journal-title":"Diabetes"},{"issue":"1","key":"2283_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.expneurol.2005.10.035","volume":"198","author":"E Uemura","year":"2006","unstructured":"Uemura E, Greenlee HW (2006) Insulin regulates neuronal glucose uptake by promoting translocation of glucose transporter GLUT3. Exp Neurol 198(1):48\u201353. https:\/\/doi.org\/10.1016\/j.expneurol.2005.10.035","journal-title":"Exp Neurol"},{"issue":"4","key":"2283_CR36","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/BF00401196","volume":"35","author":"GW Gould","year":"1992","unstructured":"Gould GW, Brant AM, Kahn BB, Shepherd PR, McCoid SC, Gibbs EM (1992) Expression of the brain-type glucose transporter is restricted to brain and neuronal cells in mice. Diabetologia 35(4):304\u2013309. https:\/\/doi.org\/10.1007\/BF00401196","journal-title":"Diabetologia"},{"issue":"11","key":"2283_CR37","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1016\/j.celrep.2019.08.019","volume":"28","author":"GT Dodd","year":"2019","unstructured":"Dodd GT, Xirouchaki CE, Eramo M, Mitchell CA, Andrews ZB, Henry BA, Cowley MA, Tiganis T (2019) Intranasal targeting of hypothalamic PTP1B and TCPTP reinstates leptin and insulin sensitivity and promotes weight loss in obesity. Cell Rep 28(11):2905\u20132922 e2905. https:\/\/doi.org\/10.1016\/j.celrep.2019.08.019","journal-title":"Cell Rep"},{"issue":"1","key":"2283_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15686-y","volume":"11","author":"S Kullmann","year":"2020","unstructured":"Kullmann S, Valenta V, Wagner R, Tschritter O, Machann J, Haring HU, Preissl H, Fritsche A et al (2020) Brain insulin sensitivity is linked to adiposity and body fat distribution. Nat Commun 11(1):1841. https:\/\/doi.org\/10.1038\/s41467-020-15686-y","journal-title":"Nat Commun"},{"issue":"4","key":"2283_CR39","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/s0031-9384(99)00220-6","volume":"68","author":"CR Park","year":"2000","unstructured":"Park CR, Seeley RJ, Craft S, Woods SC (2000) Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol Behav 68(4):509\u2013514. https:\/\/doi.org\/10.1016\/s0031-9384(99)00220-6","journal-title":"Physiol Behav"},{"issue":"49","key":"2283_CR40","doi-asserted-by":"publisher","first-page":"34893","DOI":"10.1074\/jbc.274.49.34893","volume":"274","author":"W Zhao","year":"1999","unstructured":"Zhao W, Chen H, Xu H, Moore E, Meiri N, Quon MJ, Alkon DL (1999) Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J Biol Chem 274(49):34893\u201334902. https:\/\/doi.org\/10.1074\/jbc.274.49.34893","journal-title":"J Biol Chem"},{"issue":"10","key":"2283_CR41","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.psyneuen.2004.04.003","volume":"29","author":"C Benedict","year":"2004","unstructured":"Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, Kern W (2004) Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29(10):1326\u20131334. https:\/\/doi.org\/10.1016\/j.psyneuen.2004.04.003","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"2283_CR42","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/sj.npp.1301193","volume":"32","author":"C Benedict","year":"2007","unstructured":"Benedict C, Hallschmid M, Schmitz K, Schultes B, Ratter F, Fehm HL, Born J, Kern W (2007) Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology 32(1):239\u2013243. https:\/\/doi.org\/10.1038\/sj.npp.1301193","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"2283_CR43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/s0197-4580(03)00039-3","volume":"25","author":"AA Rensink","year":"2004","unstructured":"Rensink AA, Otte-Holler I, de Boer R, Bosch RR, ten Donkelaar HJ, de Waal RM, Verbeek MM, Kremer B (2004) Insulin inhibits amyloid beta-induced cell death in cultured human brain pericytes. Neurobiol Aging 25(1):93\u2013103. https:\/\/doi.org\/10.1016\/s0197-4580(03)00039-3","journal-title":"Neurobiol Aging"},{"key":"2283_CR44","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.neurobiolaging.2018.11.008","volume":"75","author":"S Gabbouj","year":"2019","unstructured":"Gabbouj S, Natunen T, Koivisto H, Jokivarsi K, Takalo M, Marttinen M, Wittrahm R, Kemppainen S et al (2019) Intranasal insulin activates Akt2 signaling pathway in the hippocampus of wild-type but not in APP\/PS1 Alzheimer model mice. Neurobiol Aging 75:98\u2013108. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2018.11.008","journal-title":"Neurobiol Aging"},{"issue":"1","key":"2283_CR45","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1212\/wnl.50.1.164","volume":"50","author":"S Craft","year":"1998","unstructured":"Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D Jr (1998) Cerebrospinal fluid and plasma insulin levels in Alzheimer\u2019s disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 50(1):164\u2013168. https:\/\/doi.org\/10.1212\/wnl.50.1.164","journal-title":"Neurology"},{"issue":"1","key":"2283_CR46","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/jad-2005-7107","volume":"7","author":"E Steen","year":"2005","unstructured":"Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR et al (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer\u2019s disease--is this type 3 diabetes? J Alzheimers Dis 7(1):63\u201380. https:\/\/doi.org\/10.3233\/jad-2005-7107","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"2283_CR47","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nrn3880","volume":"16","author":"FL Heppner","year":"2015","unstructured":"Heppner FL, Ransohoff RM, Becher B (2015) Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 16(6):358\u2013372. https:\/\/doi.org\/10.1038\/nrn3880","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"2283_CR48","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T et al (2015) Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol 14(4):388\u2013405. https:\/\/doi.org\/10.1016\/S1474-4422(15)70016-5","journal-title":"Lancet Neurol"},{"issue":"7","key":"2283_CR49","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1172\/JCI29069","volume":"116","author":"SE Shoelson","year":"2006","unstructured":"Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116(7):1793\u20131801. https:\/\/doi.org\/10.1172\/JCI29069","journal-title":"J Clin Invest"},{"issue":"3","key":"2283_CR50","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1172\/JCI37048","volume":"119","author":"EJ Anderson","year":"2009","unstructured":"Anderson EJ, Lustig ME, Boyle KE, Woodlief TL, Kane DA, Lin CT, Price JW 3rd, Kang L et al (2009) Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest 119(3):573\u2013581. https:\/\/doi.org\/10.1172\/JCI37048","journal-title":"J Clin Invest"},{"issue":"1","key":"2283_CR51","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1096\/fj.06-7703com","volume":"22","author":"WQ Zhao","year":"2008","unstructured":"Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL (2008) Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22(1):246\u2013260. https:\/\/doi.org\/10.1096\/fj.06-7703com","journal-title":"FASEB J"},{"key":"2283_CR52","doi-asserted-by":"crossref","unstructured":"Xie L, Helmerhorst E, Taddei K, Plewright B, Van Bronswijk W, Martins R (2002) Alzheimer\u2019s beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 22 (10):RC221","DOI":"10.1523\/JNEUROSCI.22-10-j0001.2002"},{"key":"2283_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2019.103390","volume":"99","author":"CC Gali","year":"2019","unstructured":"Gali CC, Fanaee-Danesh E, Zandl-Lang M, Albrecher NM, Tam-Amersdorfer C, Stracke A, Sachdev V, Reichmann F et al (2019) Amyloid-beta impairs insulin signaling by accelerating autophagy-lysosomal degradation of LRP-1 and IR-beta in blood-brain barrier endothelial cells in vitro and in 3XTg-AD mice. Mol Cell Neurosci 99:103390. https:\/\/doi.org\/10.1016\/j.mcn.2019.103390","journal-title":"Mol Cell Neurosci"},{"issue":"3","key":"2283_CR54","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s12264-016-0034-9","volume":"32","author":"D Najem","year":"2016","unstructured":"Najem D, Bamji-Mirza M, Yang Z, Zhang W (2016) Abeta-induced insulin resistance and the effects of insulin on the cholesterol synthesis pathway and Abeta secretion in neural cells. Neurosci Bull 32(3):227\u2013238. https:\/\/doi.org\/10.1007\/s12264-016-0034-9","journal-title":"Neurosci Bull"},{"issue":"6","key":"2283_CR55","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.2337\/db11-0499","volume":"61","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Zhou B, Zhang F, Wu J, Hu Y, Liu Y, Zhai Q (2012) Amyloid-beta induces hepatic insulin resistance by activating JAK2\/STAT3\/SOCS-1 signaling pathway. Diabetes 61(6):1434\u20131443. https:\/\/doi.org\/10.2337\/db11-0499","journal-title":"Diabetes"},{"issue":"4","key":"2283_CR56","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.2337\/db12-0670","volume":"62","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Zhou B, Deng B, Zhang F, Wu J, Wang Y, Le Y, Zhai Q (2013) Amyloid-beta induces hepatic insulin resistance in vivo via JAK2. Diabetes 62(4):1159\u20131166. https:\/\/doi.org\/10.2337\/db12-0670","journal-title":"Diabetes"},{"issue":"10","key":"2283_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2020.165849","volume":"1866","author":"A Tyagi","year":"2020","unstructured":"Tyagi A, Mirita C, Taher N, Shah I, Moeller E, Tyagi A, Chong T, Pugazhenthi S (2020) Metabolic syndrome exacerbates amyloid pathology in a comorbid Alzheimer\u2019s mouse model. Biochim Biophys Acta Mol basis Dis 1866(10):165849. https:\/\/doi.org\/10.1016\/j.bbadis.2020.165849","journal-title":"Biochim Biophys Acta Mol basis Dis"},{"issue":"1","key":"2283_CR58","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s12035-019-01722-6","volume":"57","author":"C Hull","year":"2020","unstructured":"Hull C, Dekeryte R, Koss DJ, Crouch B, Buchanan H, Delibegovic M, Platt B (2020) Knock-in of mutated hTAU causes insulin resistance, inflammation and proteostasis disturbance in a mouse model of frontotemporal dementia. Mol Neurobiol 57(1):539\u2013550. https:\/\/doi.org\/10.1007\/s12035-019-01722-6","journal-title":"Mol Neurobiol"},{"key":"2283_CR59","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3389\/fncel.2019.00017","volume":"13","author":"RA Goncalves","year":"2019","unstructured":"Goncalves RA, Wijesekara N, Fraser PE, De Felice FG (2019) The link between tau and insulin signaling: implications for Alzheimer\u2019s disease and other tauopathies. Front Cell Neurosci 13:17. https:\/\/doi.org\/10.3389\/fncel.2019.00017","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"2283_CR60","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.neuron.2017.09.003","volume":"96","author":"N Zhao","year":"2017","unstructured":"Zhao N, Liu CC, Van Ingelgom AJ, Martens YA, Linares C, Knight JA, Painter MM, Sullivan PM et al (2017) Apolipoprotein E4 impairs neuronal insulin signaling by trapping insulin receptor in the endosomes. Neuron 96(1):115\u2013129 e115. https:\/\/doi.org\/10.1016\/j.neuron.2017.09.003","journal-title":"Neuron"},{"key":"2283_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/srep26119","volume":"6","author":"ES Chan","year":"2016","unstructured":"Chan ES, Shetty MS, Sajikumar S, Chen C, Soong TW, Wong BS (2016) ApoE4 expression accelerates hippocampus-dependent cognitive deficits by enhancing Abeta impairment of insulin signaling in an Alzheimer\u2019s disease mouse model. Sci Rep 6:26119. https:\/\/doi.org\/10.1038\/srep26119","journal-title":"Sci Rep"},{"issue":"1","key":"2283_CR62","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3233\/ADR-200238","volume":"4","author":"J Robbins","year":"2020","unstructured":"Robbins J, Busquets O, Tong M, de la Monte SM (2020) Dysregulation of insulin-linked metabolic pathways in Alzheimer\u2019s disease: co-factor role of apolipoprotein E varepsilon4. J Alzheimers Dis Rep 4(1):479\u2013493. https:\/\/doi.org\/10.3233\/ADR-200238","journal-title":"J Alzheimers Dis Rep"},{"issue":"7","key":"2283_CR63","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.2337\/db16-1444","volume":"66","author":"JS Neergaard","year":"2017","unstructured":"Neergaard JS, Dragsbaek K, Christiansen C, Nielsen HB, Brix S, Karsdal MA, Henriksen K (2017) Metabolic syndrome, insulin resistance, and cognitive dysfunction: does your metabolic profile affect your brain? Diabetes 66(7):1957\u20131963. https:\/\/doi.org\/10.2337\/db16-1444","journal-title":"Diabetes"},{"key":"2283_CR64","doi-asserted-by":"publisher","unstructured":"Fan YC, Chou CC, You SL, Sun CA, Chen CJ, Bai CH (2017) Impact of worsened metabolic syndrome on the risk of dementia: a nationwide cohort study. J Am Heart Assoc 6(9). https:\/\/doi.org\/10.1161\/JAHA.116.004749","DOI":"10.1161\/JAHA.116.004749"},{"key":"2283_CR65","doi-asserted-by":"publisher","unstructured":"Lee JE, Shin DW, Han K, Kim D, Yoo JE, Lee J, Kim S, Son KY et al (2020) Changes in metabolic syndrome status and risk of dementia. J Clin Med 9(1). https:\/\/doi.org\/10.3390\/jcm9010122","DOI":"10.3390\/jcm9010122"},{"issue":"36","key":"2283_CR66","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004791","volume":"95","author":"CK Tsai","year":"2016","unstructured":"Tsai CK, Kao TW, Lee JT, Wu CJ, Hueng DY, Liang CS, Wang GC, Yang FC et al (2016) Increased risk of cognitive impairment in patients with components of metabolic syndrome. Medicine (Baltimore) 95(36):e4791. https:\/\/doi.org\/10.1097\/MD.0000000000004791","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"2283_CR67","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/ene.12845","volume":"23","author":"N Hishikawa","year":"2016","unstructured":"Hishikawa N, Fukui Y, Sato K, Kono S, Yamashita T, Ohta Y, Deguchi K, Abe K (2016) Cognitive and affective functions in Alzheimer\u2019s disease patients with metabolic syndrome. Eur J Neurol 23(2):339\u2013345. https:\/\/doi.org\/10.1111\/ene.12845","journal-title":"Eur J Neurol"},{"issue":"13","key":"2283_CR68","doi-asserted-by":"publisher","first-page":"e1150","DOI":"10.1212\/WNL.0000000000005214","volume":"90","author":"LL Ekblad","year":"2018","unstructured":"Ekblad LL, Johansson J, Helin S, Viitanen M, Laine H, Puukka P, Jula A, Rinne JO (2018) Midlife insulin resistance, APOE genotype, and late-life brain amyloid accumulation. Neurology 90(13):e1150\u2013e1157. https:\/\/doi.org\/10.1212\/WNL.0000000000005214","journal-title":"Neurology"},{"issue":"6","key":"2283_CR69","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jagp.2019.01.214","volume":"27","author":"AR Atti","year":"2019","unstructured":"Atti AR, Valente S, Iodice A, Caramella I, Ferrari B, Albert U, Mandelli L, De Ronchi D (2019) Metabolic syndrome, mild cognitive impairment, and dementia: a meta-analysis of longitudinal studies. Am J Geriatr Psychiatry 27(6):625\u2013637. https:\/\/doi.org\/10.1016\/j.jagp.2019.01.214","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"2283_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33843-8","volume":"8","author":"N Mallorqui-Bague","year":"2018","unstructured":"Mallorqui-Bague N, Lozano-Madrid M, Toledo E, Corella D, Salas-Salvado J, Cuenca-Royo A, Vioque J, Romaguera D et al (2018) Type 2 diabetes and cognitive impairment in an older population with overweight or obesity and metabolic syndrome: baseline cross-sectional analysis of the PREDIMED-plus study. Sci Rep 8(1):16128. https:\/\/doi.org\/10.1038\/s41598-018-33843-8","journal-title":"Sci Rep"},{"issue":"11","key":"2283_CR71","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00127-018-1581-3","volume":"53","author":"K Pal","year":"2018","unstructured":"Pal K, Mukadam N, Petersen I, Cooper C (2018) Mild cognitive impairment and progression to dementia in people with diabetes, prediabetes and metabolic syndrome: a systematic review and meta-analysis. Soc Psychiatry Psychiatr Epidemiol 53(11):1149\u20131160. https:\/\/doi.org\/10.1007\/s00127-018-1581-3","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"14","key":"2283_CR72","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.2174\/1567205017666200103111253","volume":"16","author":"XY Li","year":"2019","unstructured":"Li XY, Zhang M, Xu W, Li JQ, Cao XP, Yu JT, Tan L (2019) Midlife modifiable risk factors for dementia: a systematic review and meta-analysis of 34 prospective cohort studies. Curr Alzheimer Res 16(14):1254\u20131268. https:\/\/doi.org\/10.2174\/1567205017666200103111253","journal-title":"Curr Alzheimer Res"},{"issue":"4","key":"2283_CR73","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3233\/JAD-200145","volume":"76","author":"T Pekkala","year":"2020","unstructured":"Pekkala T, Hall A, Mangialasche F, Kemppainen N, Mecocci P, Ngandu T, Rinne JO, Soininen H et al (2020) Association of peripheral insulin resistance and other markers of type 2 diabetes mellitus with brain amyloid deposition in healthy individuals at risk of dementia. J Alzheimers Dis 76(4):1243\u20131248. https:\/\/doi.org\/10.3233\/JAD-200145","journal-title":"J Alzheimers Dis"},{"key":"2283_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104772","volume":"137","author":"A Tramutola","year":"2020","unstructured":"Tramutola A, Lanzillotta C, Di Domenico F, Head E, Butterfield DA, Perluigi M, Barone E (2020) Brain insulin resistance triggers early onset Alzheimer disease in Down syndrome. Neurobiol Dis 137:104772. https:\/\/doi.org\/10.1016\/j.nbd.2020.104772","journal-title":"Neurobiol Dis"},{"issue":"14","key":"2283_CR75","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1212\/01.wnl.0000306313.89165.ef","volume":"71","author":"RA Whitmer","year":"2008","unstructured":"Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K (2008) Central obesity and increased risk of dementia more than three decades later. Neurology 71(14):1057\u20131064. https:\/\/doi.org\/10.1212\/01.wnl.0000306313.89165.ef","journal-title":"Neurology"},{"issue":"7504","key":"2283_CR76","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1136\/bmj.38446.466238.E0","volume":"330","author":"RA Whitmer","year":"2005","unstructured":"Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP Jr, Yaffe K (2005) Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 330(7504):1360. https:\/\/doi.org\/10.1136\/bmj.38446.466238.E0","journal-title":"BMJ"},{"issue":"8","key":"2283_CR77","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/ijo.2009.104","volume":"33","author":"LB Hassing","year":"2009","unstructured":"Hassing LB, Dahl AK, Thorvaldsson V, Berg S, Gatz M, Pedersen NL, Johansson B (2009) Overweight in midlife and risk of dementia: a 40-year follow-up study. Int J Obes 33(8):893\u2013898. https:\/\/doi.org\/10.1038\/ijo.2009.104","journal-title":"Int J Obes"},{"issue":"5","key":"2283_CR78","doi-asserted-by":"publisher","first-page":"e426","DOI":"10.1111\/j.1467-789X.2010.00825.x","volume":"12","author":"KJ Anstey","year":"2011","unstructured":"Anstey KJ, Cherbuin N, Budge M, Young J (2011) Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes Rev 12(5):e426\u2013e437. https:\/\/doi.org\/10.1111\/j.1467-789X.2010.00825.x","journal-title":"Obes Rev"},{"issue":"9","key":"2283_CR79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099305","volume":"9","author":"B Nepal","year":"2014","unstructured":"Nepal B, Brown LJ, Anstey KJ (2014) Rising midlife obesity will worsen future prevalence of dementia. PLoS One 9(9):e99305. https:\/\/doi.org\/10.1371\/journal.pone.0099305","journal-title":"PLoS One"},{"issue":"7","key":"2283_CR80","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1210\/jc.2018-01491","volume":"104","author":"JY Lee","year":"2019","unstructured":"Lee JY, Han K, Han E, Kim G, Cho H, Kim KJ, Lee BW, Kang ES et al (2019) Risk of incident dementia according to metabolic health and obesity status in late life: a population-based cohort study. J Clin Endocrinol Metab 104(7):2942\u20132952. https:\/\/doi.org\/10.1210\/jc.2018-01491","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2283_CR81","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/ijo.2017.231","volume":"42","author":"WA Banks","year":"2018","unstructured":"Banks WA, Farr SA, Salameh TS, Niehoff ML, Rhea EM, Morley JE, Hanson AJ, Hansen KM et al (2018) Triglycerides cross the blood-brain barrier and induce central leptin and insulin receptor resistance. Int J Obes 42(3):391\u2013397. https:\/\/doi.org\/10.1038\/ijo.2017.231","journal-title":"Int J Obes"},{"issue":"1","key":"2283_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MOL.0000000000000656","volume":"31","author":"KJ Mukamal","year":"2020","unstructured":"Mukamal KJ (2020) Nonesterified fatty acids, cognitive decline, and dementia. Curr Opin Lipidol 31(1):1\u20137. https:\/\/doi.org\/10.1097\/MOL.0000000000000656","journal-title":"Curr Opin Lipidol"},{"issue":"5","key":"2283_CR83","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1037\/0735-7044.119.5.1389","volume":"119","author":"G Winocur","year":"2005","unstructured":"Winocur G, Greenwood CE, Piroli GG, Grillo CA, Reznikov LR, Reagan LP, McEwen BS (2005) Memory impairment in obese Zucker rats: an investigation of cognitive function in an animal model of insulin resistance and obesity. Behav Neurosci 119(5):1389\u20131395. https:\/\/doi.org\/10.1037\/0735-7044.119.5.1389","journal-title":"Behav Neurosci"},{"issue":"3","key":"2283_CR84","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/0196-9781(90)90044-6","volume":"11","author":"MW Schwartz","year":"1990","unstructured":"Schwartz MW, Figlewicz DF, Kahn SE, Baskin DG, Greenwood MR, Porte D Jr (1990) Insulin binding to brain capillaries is reduced in genetically obese, hyperinsulinemic Zucker rats. Peptides 11(3):467\u2013472. https:\/\/doi.org\/10.1016\/0196-9781(90)90044-6","journal-title":"Peptides"},{"issue":"1","key":"2283_CR85","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0197-0186(90)90129-h","volume":"16","author":"S Ohkuma","year":"1990","unstructured":"Ohkuma S, Ma FH, Kishi M, Kuriyama K (1990) Alteration of acetylcholine metabolism in the brain of Zucker fatty rat. Neurochem Int 16(1):99\u2013103. https:\/\/doi.org\/10.1016\/0197-0186(90)90129-h","journal-title":"Neurochem Int"},{"issue":"3","key":"2283_CR86","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1159\/000373947","volume":"35","author":"H Raza","year":"2015","unstructured":"Raza H, John A, Howarth FC (2015) Increased oxidative stress and mitochondrial dysfunction in Zucker diabetic rat liver and brain. Cell Physiol Biochem 35(3):1241\u20131251. https:\/\/doi.org\/10.1159\/000373947","journal-title":"Cell Physiol Biochem"},{"issue":"4","key":"2283_CR87","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1210\/endo-117-4-1537","volume":"117","author":"DP Figlewicz","year":"1985","unstructured":"Figlewicz DP, Dorsa DM, Stein LJ, Baskin DG, Paquette T, Greenwood MR, Woods SC, Porte D Jr (1985) Brain and liver insulin binding is decreased in Zucker rats carrying the \u2018fa\u2019 gene. Endocrinology 117(4):1537\u20131543. https:\/\/doi.org\/10.1210\/endo-117-4-1537","journal-title":"Endocrinology"},{"issue":"5","key":"2283_CR88","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/jcbfm.2010.27","volume":"30","author":"T Liistro","year":"2010","unstructured":"Liistro T, Guiducci L, Burchielli S, Panetta D, Belcari N, Pardini S, Del Guerra A, Salvadori PA et al (2010) Brain glucose overexposure and lack of acute metabolic flexibility in obesity and type 2 diabetes: a PET-[18F]FDG study in Zucker and ZDF rats. J Cereb Blood Flow Metab 30(5):895\u2013899. https:\/\/doi.org\/10.1038\/jcbfm.2010.27","journal-title":"J Cereb Blood Flow Metab"},{"key":"2283_CR89","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.neulet.2013.03.025","volume":"543","author":"D Tomassoni","year":"2013","unstructured":"Tomassoni D, Nwankwo IE, Gabrielli MG, Bhatt S, Muhammad AB, Lokhandwala MF, Tayebati SK, Amenta F (2013) Astrogliosis in the brain of obese Zucker rat: a model of metabolic syndrome. Neurosci Lett 543:136\u2013141. https:\/\/doi.org\/10.1016\/j.neulet.2013.03.025","journal-title":"Neurosci Lett"},{"issue":"12","key":"2283_CR90","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.2174\/1567205013666160401114751","volume":"13","author":"L Qin","year":"2016","unstructured":"Qin L, Chong T, Rodriguez R, Pugazhenthi S (2016) Glucagon-like peptide-1-mediated modulation of inflammatory pathways in the diabetic brain: relevance to Alzheimer\u2019s disease. Curr Alzheimer Res 13(12):1346\u20131355. https:\/\/doi.org\/10.2174\/1567205013666160401114751","journal-title":"Curr Alzheimer Res"},{"issue":"3","key":"2283_CR91","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/s0306-4522(02)00162-8","volume":"113","author":"XL Li","year":"2002","unstructured":"Li XL, Aou S, Oomura Y, Hori N, Fukunaga K, Hori T (2002) Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience 113(3):607\u2013615. https:\/\/doi.org\/10.1016\/s0306-4522(02)00162-8","journal-title":"Neuroscience"},{"issue":"1","key":"2283_CR92","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.bbadis.2016.11.003","volume":"1863","author":"H Zheng","year":"2017","unstructured":"Zheng H, Zheng Y, Zhao L, Chen M, Bai G, Hu Y, Hu W, Yan Z et al (2017) Cognitive decline in type 2 diabetic db\/db mice may be associated with brain region-specific metabolic disorders. Biochim Biophys Acta Mol basis Dis 1863(1):266\u2013273. https:\/\/doi.org\/10.1016\/j.bbadis.2016.11.003","journal-title":"Biochim Biophys Acta Mol basis Dis"},{"key":"2283_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2019.111978","volume":"371","author":"LM Yermakov","year":"2019","unstructured":"Yermakov LM, Griggs RB, Drouet DE, Sugimoto C, Williams MT, Vorhees CV, Susuki K (2019) Impairment of cognitive flexibility in type 2 diabetic db\/db mice. Behav Brain Res 371:111978. https:\/\/doi.org\/10.1016\/j.bbr.2019.111978","journal-title":"Behav Brain Res"},{"key":"2283_CR94","doi-asserted-by":"publisher","unstructured":"Jiang Y, Lin L, Liu N, Wang Q, Yuan J, Li Y, Chung KK, Guo S et al (2020) FGF21 protects against aggravated blood-brain barrier disruption after ischemic focal stroke in diabetic db\/db male mice via cerebrovascular PPARgamma activation. Int J Mol Sci 21(3). https:\/\/doi.org\/10.3390\/ijms21030824","DOI":"10.3390\/ijms21030824"},{"key":"2283_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2020.104790","volume":"139","author":"R Kumari","year":"2020","unstructured":"Kumari R, Bettermann K, Willing L, Sinha K, Simpson IA (2020) The role of neutrophils in mediating stroke injury in the diabetic db\/db mouse brain following hypoxia-ischemia. Neurochem Int 139:104790. https:\/\/doi.org\/10.1016\/j.neuint.2020.104790","journal-title":"Neurochem Int"},{"key":"2283_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2016.10.004","volume":"98","author":"M Gratuze","year":"2017","unstructured":"Gratuze M, El Khoury NB, Turgeon A, Julien C, Marcouiller F, Morin F, Whittington RA, Marette A et al (2017) Tau hyperphosphorylation in the brain of ob\/ob mice is due to hypothermia: Importance of thermoregulation in linking diabetes and Alzheimer\u2019s disease. Neurobiol Dis 98:1\u20138. https:\/\/doi.org\/10.1016\/j.nbd.2016.10.004","journal-title":"Neurobiol Dis"},{"key":"2283_CR97","doi-asserted-by":"publisher","unstructured":"Schepers J, Gebhardt C, Bracke A, Eiffler I, von Bohlen Und Halbach O (2020) Structural and functional consequences in the amygdala of leptin-deficient mice. Cell Tissue Res. https:\/\/doi.org\/10.1007\/s00441-020-03266-x","DOI":"10.1007\/s00441-020-03266-x"},{"key":"2283_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2020.104674","volume":"117","author":"X Qin","year":"2020","unstructured":"Qin X, Wang W, Wu H, Liu D, Wang R, Xu J, Jiang H, Pan F (2020) PPARgamma-mediated microglial activation phenotype is involved in depressive-like behaviors and neuroinflammation in stressed C57BL\/6J and ob\/ob mice. Psychoneuroendocrinology 117:104674. https:\/\/doi.org\/10.1016\/j.psyneuen.2020.104674","journal-title":"Psychoneuroendocrinology"},{"issue":"15","key":"2283_CR99","doi-asserted-by":"publisher","first-page":"7036","DOI":"10.1073\/pnas.1000645107","volume":"107","author":"S Takeda","year":"2010","unstructured":"Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, Kurinami H, Shinohara M et al (2010) Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A 107(15):7036\u20137041. https:\/\/doi.org\/10.1073\/pnas.1000645107","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2283_CR100","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1096\/fj.201901028RR","volume":"34","author":"M Shinohara","year":"2020","unstructured":"Shinohara M, Tashiro Y, Shinohara M, Hirokawa J, Suzuki K, Onishi-Takeya M, Mukouzono M, Takeda S et al (2020) Increased levels of Abeta42 decrease the lifespan of ob\/ob mice with dysregulation of microglia and astrocytes. FASEB J 34(2):2425\u20132435. https:\/\/doi.org\/10.1096\/fj.201901028RR","journal-title":"FASEB J"},{"issue":"2","key":"2283_CR101","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s12640-017-9821-y","volume":"36","author":"FM Girault","year":"2019","unstructured":"Girault FM, Sonnay S, Gruetter R, Duarte JMN (2019) Alterations of brain energy metabolism in type 2 diabetic Goto-Kakizaki rats measured in vivo by (13)C magnetic resonance spectroscopy. Neurotox Res 36(2):268\u2013278. https:\/\/doi.org\/10.1007\/s12640-017-9821-y","journal-title":"Neurotox Res"},{"issue":"3","key":"2283_CR102","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/dmrr.200","volume":"17","author":"MS Santos","year":"2001","unstructured":"Santos MS, Santos DL, Palmeira CM, Seica R, Moreno AJ, Oliveira CR (2001) Brain and liver mitochondria isolated from diabetic Goto-Kakizaki rats show different susceptibility to induced oxidative stress. Diabetes Metab Res Rev 17(3):223\u2013230. https:\/\/doi.org\/10.1002\/dmrr.200","journal-title":"Diabetes Metab Res Rev"},{"issue":"8","key":"2283_CR103","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1002\/jnr.24437","volume":"97","author":"AF Soares","year":"2019","unstructured":"Soares AF, Nissen JD, Garcia-Serrano AM, Nussbaum SS, Waagepetersen HS, Duarte JMN (2019) Glycogen metabolism is impaired in the brain of male type 2 diabetic Goto-Kakizaki rats. J Neurosci Res 97(8):1004\u20131017. https:\/\/doi.org\/10.1002\/jnr.24437","journal-title":"J Neurosci Res"},{"issue":"6","key":"2283_CR104","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2337\/diabetes.52.6.1449","volume":"52","author":"PI Moreira","year":"2003","unstructured":"Moreira PI, Santos MS, Moreno AM, Seica R, Oliveira CR (2003) Increased vulnerability of brain mitochondria in diabetic (Goto-Kakizaki) rats with aging and amyloid-beta exposure. Diabetes 52(6):1449\u20131456. https:\/\/doi.org\/10.2337\/diabetes.52.6.1449","journal-title":"Diabetes"},{"issue":"4","key":"2283_CR105","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.neuroscience.2006.10.054","volume":"144","author":"T Moreira","year":"2007","unstructured":"Moreira T, Cebers G, Pickering C, Ostenson CG, Efendic S, Liljequist S (2007) Diabetic Goto-Kakizaki rats display pronounced hyperglycemia and longer-lasting cognitive impairments following ischemia induced by cortical compression. Neuroscience 144(4):1169\u20131185. https:\/\/doi.org\/10.1016\/j.neuroscience.2006.10.054","journal-title":"Neuroscience"},{"issue":"3","key":"2283_CR106","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3233\/JAD-122017","volume":"34","author":"XH Li","year":"2013","unstructured":"Li XH, Xin X, Wang Y, Wu JZ, Jin ZD, Ma LN, Nie CJ, Xiao X et al (2013) Pentamethylquercetin protects against diabetes-related cognitive deficits in diabetic Goto-Kakizaki rats. J Alzheimers Dis 34(3):755\u2013767. https:\/\/doi.org\/10.3233\/JAD-122017","journal-title":"J Alzheimers Dis"},{"key":"2283_CR107","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.neulet.2017.06.041","volume":"655","author":"H Pintana","year":"2017","unstructured":"Pintana H, Apaijai N, Kerdphoo S, Pratchayasakul W, Sripetchwandee J, Suntornsaratoon P, Charoenphandhu N, Chattipakorn N et al (2017) Hyperglycemia induced the Alzheimer\u2019s proteins and promoted loss of synaptic proteins in advanced-age female Goto-Kakizaki (GK) rats. Neurosci Lett 655:41\u201345. https:\/\/doi.org\/10.1016\/j.neulet.2017.06.041","journal-title":"Neurosci Lett"},{"issue":"6","key":"2283_CR108","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2337\/dc12-0413","volume":"35","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A et al (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6):1364\u20131379. https:\/\/doi.org\/10.2337\/dc12-0413","journal-title":"Diabetes Care"},{"issue":"2","key":"2283_CR109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212293","volume":"14","author":"G Weinstein","year":"2019","unstructured":"Weinstein G, Davis-Plourde KL, Conner S, Himali JJ, Beiser AS, Lee A, Rawlings AM, Sedaghat S et al (2019) Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer\u2019s disease: Pooled analysis from 5 cohorts. PLoS One 14(2):e0212293. https:\/\/doi.org\/10.1371\/journal.pone.0212293","journal-title":"PLoS One"},{"issue":"7","key":"2283_CR110","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00415-018-8768-0","volume":"265","author":"KI Avgerinos","year":"2018","unstructured":"Avgerinos KI, Kalaitzidis G, Malli A, Kalaitzoglou D, Myserlis PG, Lioutas VA (2018) Intranasal insulin in Alzheimer\u2019s dementia or mild cognitive impairment: a systematic review. J Neurol 265(7):1497\u20131510. https:\/\/doi.org\/10.1007\/s00415-018-8768-0","journal-title":"J Neurol"},{"issue":"1","key":"2283_CR111","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/archneurol.2011.233","volume":"69","author":"S Craft","year":"2012","unstructured":"Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M et al (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69(1):29\u201338. https:\/\/doi.org\/10.1001\/archneurol.2011.233","journal-title":"Arch Neurol"},{"issue":"3","key":"2283_CR112","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3233\/JAD-141791","volume":"44","author":"A Claxton","year":"2015","unstructured":"Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, Callaghan M, Arbuckle M et al (2015) Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer\u2019s disease dementia. J Alzheimers Dis 44(3):897\u2013906. https:\/\/doi.org\/10.3233\/JAD-141791","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"2283_CR113","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3233\/JAD-180578","volume":"69","author":"M Mustapic","year":"2019","unstructured":"Mustapic M, Tran J, Craft S, Kapogiannis D (2019) Extracellular vesicle biomarkers track cognitive changes following intranasal insulin in Alzheimer\u2019s disease. J Alzheimers Dis 69(2):489\u2013498. https:\/\/doi.org\/10.3233\/JAD-180578","journal-title":"J Alzheimers Dis"},{"key":"2283_CR114","doi-asserted-by":"publisher","unstructured":"Craft S, Raman R, Chow TW, Rafii MS, Sun CK, Rissman RA, Donohue MC, Brewer JB et al (2020) Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1840","DOI":"10.1001\/jamaneurol.2020.1840"},{"key":"2283_CR115","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.expneurol.2014.06.004","volume":"261","author":"Y Chen","year":"2014","unstructured":"Chen Y, Zhao Y, Dai CL, Liang Z, Run X, Iqbal K, Liu F, Gong CX (2014) Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Abeta level and microglia activation in the brains of 3xTg-AD mice. Exp Neurol 261:610\u2013619. https:\/\/doi.org\/10.1016\/j.expneurol.2014.06.004","journal-title":"Exp Neurol"},{"issue":"3","key":"2283_CR116","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1096\/fj.201802043R","volume":"33","author":"GN Ruegsegger","year":"2019","unstructured":"Ruegsegger GN, Manjunatha S, Summer P, Gopala S, Zabeilski P, Dasari S, Vanderboom PM, Lanza IR et al (2019) Insulin deficiency and intranasal insulin alter brain mitochondrial function: a potential factor for dementia in diabetes. FASEB J 33(3):4458\u20134472. https:\/\/doi.org\/10.1096\/fj.201802043R","journal-title":"FASEB J"},{"issue":"5","key":"2283_CR117","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1177\/0271678X17709709","volume":"38","author":"SK Swaminathan","year":"2018","unstructured":"Swaminathan SK, Ahlschwede KM, Sarma V, Curran GL, Omtri RS, Decklever T, Lowe VJ, Poduslo JF et al (2018) Insulin differentially affects the distribution kinetics of amyloid beta 40 and 42 in plasma and brain. J Cereb Blood Flow Metab 38(5):904\u2013918. https:\/\/doi.org\/10.1177\/0271678X17709709","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"2283_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-44635-z","volume":"9","author":"W Franklin","year":"2019","unstructured":"Franklin W, Krishnan B, Taglialatela G (2019) Chronic synaptic insulin resistance after traumatic brain injury abolishes insulin protection from amyloid beta and tau oligomer-induced synaptic dysfunction. Sci Rep 9(1):8228. https:\/\/doi.org\/10.1038\/s41598-019-44635-z","journal-title":"Sci Rep"},{"issue":"3","key":"2283_CR119","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3233\/JAD-2011-101524","volume":"24","author":"CC Hsu","year":"2011","unstructured":"Hsu CC, Wahlqvist ML, Lee MS, Tsai HN (2011) Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis 24(3):485\u2013493. https:\/\/doi.org\/10.3233\/JAD-2011-101524","journal-title":"J Alzheimers Dis"},{"key":"2283_CR120","doi-asserted-by":"publisher","unstructured":"Samaras K, Makkar S, Crawford JD, Kochan NA, Wen W, Draper B, Trollor JN, Brodaty H et al (2020) Metformin use is associated with slowed cognitive decline and reduced incident dementia in older adults with type 2 diabetes: The Sydney Memory and Ageing Study. Diabetes Care. https:\/\/doi.org\/10.2337\/dc20-0892","DOI":"10.2337\/dc20-0892"},{"issue":"5","key":"2283_CR121","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/j.1532-5415.2012.03916.x","volume":"60","author":"P Imfeld","year":"2012","unstructured":"Imfeld P, Bodmer M, Jick SS, Meier CR (2012) Metformin, other antidiabetic drugs, and risk of Alzheimer\u2019s disease: a population-based case-control study. J Am Geriatr Soc 60(5):916\u2013921. https:\/\/doi.org\/10.1111\/j.1532-5415.2012.03916.x","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"2283_CR122","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00607-4","volume":"12","author":"C Hierro-Bujalance","year":"2020","unstructured":"Hierro-Bujalance C, Infante-Garcia C, Del Marco A, Herrera M, Carranza-Naval MJ, Suarez J, Alves-Martinez P, Lubian-Lopez S et al (2020) Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer\u2019s disease and type 2 diabetes. Alzheimers Res Ther 12(1):40. https:\/\/doi.org\/10.1186\/s13195-020-00607-4","journal-title":"Alzheimers Res Ther"},{"key":"2283_CR123","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-014-0148-1","volume":"13","author":"B Lin","year":"2014","unstructured":"Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, Ma M, Nakagawa T et al (2014) Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol 13:148. https:\/\/doi.org\/10.1186\/s12933-014-0148-1","journal-title":"Cardiovasc Diabetol"},{"key":"2283_CR124","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.taap.2017.08.005","volume":"333","author":"P Sa-Nguanmoo","year":"2017","unstructured":"Sa-Nguanmoo P, Tanajak P, Kerdphoo S, Jaiwongkam T, Pratchayasakul W, Chattipakorn N, Chattipakorn SC (2017) SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. Toxicol Appl Pharmacol 333:43\u201350. https:\/\/doi.org\/10.1016\/j.taap.2017.08.005","journal-title":"Toxicol Appl Pharmacol"},{"key":"2283_CR125","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.bioorg.2018.02.009","volume":"77","author":"MJ Nanjan","year":"2018","unstructured":"Nanjan MJ, Mohammed M, Prashantha Kumar BR, Chandrasekar MJN (2018) Thiazolidinediones as antidiabetic agents: a critical review. Bioorg Chem 77:548\u2013567. https:\/\/doi.org\/10.1016\/j.bioorg.2018.02.009","journal-title":"Bioorg Chem"},{"issue":"4","key":"2283_CR126","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/sj.tpj.6500369","volume":"6","author":"ME Risner","year":"2006","unstructured":"Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA et al (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer\u2019s disease. Pharmacogenomics J 6(4):246\u2013254. https:\/\/doi.org\/10.1038\/sj.tpj.6500369","journal-title":"Pharmacogenomics J"},{"issue":"11","key":"2283_CR127","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1176\/appi.ajgp.13.11.950","volume":"13","author":"GS Watson","year":"2005","unstructured":"Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ et al (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13(11):950\u2013958. https:\/\/doi.org\/10.1176\/appi.ajgp.13.11.950","journal-title":"Am J Geriatr Psychiatry"},{"issue":"8","key":"2283_CR128","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.2337\/dc09-2030","volume":"33","author":"AM Abbatecola","year":"2010","unstructured":"Abbatecola AM, Lattanzio F, Molinari AM, Cioffi M, Mansi L, Rambaldi P, DiCioccio L, Cacciapuoti F et al (2010) Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment. Diabetes Care 33(8):1706\u20131711. https:\/\/doi.org\/10.2337\/dc09-2030","journal-title":"Diabetes Care"},{"issue":"2","key":"2283_CR129","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000318845","volume":"30","author":"M Gold","year":"2010","unstructured":"Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G et al (2010) Rosiglitazone monotherapy in mild-to-moderate Alzheimer\u2019s disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 30(2):131\u2013146. https:\/\/doi.org\/10.1159\/000318845","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"2283_CR130","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.bbr.2010.08.002","volume":"216","author":"J Rodriguez-Rivera","year":"2011","unstructured":"Rodriguez-Rivera J, Denner L, Dineley KT (2011) Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status. Behav Brain Res 216(1):255\u2013261. https:\/\/doi.org\/10.1016\/j.bbr.2010.08.002","journal-title":"Behav Brain Res"},{"issue":"7","key":"2283_CR131","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/npp.2010.32","volume":"35","author":"L Escribano","year":"2010","unstructured":"Escribano L, Simon AM, Gimeno E, Cuadrado-Tejedor M, Lopez de Maturana R, Garcia-Osta A, Ricobaraza A, Perez-Mediavilla A et al (2010) Rosiglitazone rescues memory impairment in Alzheimer\u2019s transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 35(7):1593\u20131604. https:\/\/doi.org\/10.1038\/npp.2010.32","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"2283_CR132","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1210\/en.2011-1502","volume":"153","author":"N Pipatpiboon","year":"2012","unstructured":"Pipatpiboon N, Pratchayasakul W, Chattipakorn N, Chattipakorn SC (2012) PPARgamma agonist improves neuronal insulin receptor function in hippocampus and brain mitochondria function in rats with insulin resistance induced by long term high-fat diets. Endocrinology 153(1):329\u2013338. https:\/\/doi.org\/10.1210\/en.2011-1502","journal-title":"Endocrinology"},{"issue":"1\u20133","key":"2283_CR133","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ejphar.2008.06.016","volume":"589","author":"AR Pathan","year":"2008","unstructured":"Pathan AR, Gaikwad AB, Viswanad B, Ramarao P (2008) Rosiglitazone attenuates the cognitive deficits induced by high fat diet feeding in rats. Eur J Pharmacol 589(1\u20133):176\u2013179. https:\/\/doi.org\/10.1016\/j.ejphar.2008.06.016","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2283_CR134","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3233\/jad-2007-11108","volume":"11","author":"JC Strum","year":"2007","unstructured":"Strum JC, Shehee R, Virley D, Richardson J, Mattie M, Selley P, Ghosh S, Nock C et al (2007) Rosiglitazone induces mitochondrial biogenesis in mouse brain. J Alzheimers Dis 11(1):45\u201351. https:\/\/doi.org\/10.3233\/jad-2007-11108","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"2283_CR135","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3233\/JAD-2012-111661","volume":"30","author":"JL Searcy","year":"2012","unstructured":"Searcy JL, Phelps JT, Pancani T, Kadish I, Popovic J, Anderson KL, Beckett TL, Murphy MP et al (2012) Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer\u2019s disease. J Alzheimers Dis 30(4):943\u2013961. https:\/\/doi.org\/10.3233\/JAD-2012-111661","journal-title":"J Alzheimers Dis"},{"issue":"37","key":"2283_CR136","doi-asserted-by":"publisher","first-page":"9287","DOI":"10.1523\/JNEUROSCI.3348-08.2008","volume":"28","author":"N Nicolakakis","year":"2008","unstructured":"Nicolakakis N, Aboulkassim T, Ongali B, Lecrux C, Fernandes P, Rosa-Neto P, Tong XK, Hamel E (2008) Complete rescue of cerebrovascular function in aged Alzheimer\u2019s disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J Neurosci 28(37):9287\u20139296. https:\/\/doi.org\/10.1523\/JNEUROSCI.3348-08.2008","journal-title":"J Neurosci"},{"issue":"3","key":"2283_CR137","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1177\/0271678X16655172","volume":"37","author":"A Badhwar","year":"2017","unstructured":"Badhwar A, Brown R, Stanimirovic DB, Haqqani AS, Hamel E (2017) Proteomic differences in brain vessels of Alzheimer\u2019s disease mice: normalization by PPARgamma agonist pioglitazone. J Cereb Blood Flow Metab 37(3):1120\u20131136. https:\/\/doi.org\/10.1177\/0271678X16655172","journal-title":"J Cereb Blood Flow Metab"},{"issue":"7","key":"2283_CR138","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068612","volume":"8","author":"P Papadopoulos","year":"2013","unstructured":"Papadopoulos P, Rosa-Neto P, Rochford J, Hamel E (2013) Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer\u2019s disease with combined amyloid-beta and cerebrovascular pathology. PLoS One 8(7):e68612. https:\/\/doi.org\/10.1371\/journal.pone.0068612","journal-title":"PLoS One"},{"issue":"Suppl 2","key":"2283_CR139","first-page":"S205","volume":"4","author":"L Dehghani","year":"2013","unstructured":"Dehghani L, Meamar R, Askari G, Khorvash F, Shaygannejad V, Pour AF, Javanmard SH (2013) The effect of pioglitazone on the Alzheimer\u2019s disease-induced apoptosis in human umbilical vein endothelial cells. Int J Prev Med 4(Suppl 2):S205\u2013S210","journal-title":"Int J Prev Med"},{"key":"2283_CR140","doi-asserted-by":"publisher","DOI":"10.1038\/srep09000","volume":"5","author":"KL Chang","year":"2015","unstructured":"Chang KL, Pee HN, Yang S, Ho PC (2015) Influence of drug transporters and stereoselectivity on the brain penetration of pioglitazone as a potential medicine against Alzheimer\u2019s disease. Sci Rep 5:9000. https:\/\/doi.org\/10.1038\/srep09000","journal-title":"Sci Rep"},{"issue":"1","key":"2283_CR141","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.expneurol.2010.10.003","volume":"227","author":"A Sauerbeck","year":"2011","unstructured":"Sauerbeck A, Gao J, Readnower R, Liu M, Pauly JR, Bing G, Sullivan PG (2011) Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. Exp Neurol 227(1):128\u2013135. https:\/\/doi.org\/10.1016\/j.expneurol.2010.10.003","journal-title":"Exp Neurol"},{"issue":"3","key":"2283_CR142","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059313","volume":"8","author":"QQ Yin","year":"2013","unstructured":"Yin QQ, Pei JJ, Xu S, Luo DZ, Dong SQ, Sun MH, You L, Sun ZJ et al (2013) Pioglitazone improves cognitive function via increasing insulin sensitivity and strengthening antioxidant defense system in fructose-drinking insulin resistance rats. PLoS One 8(3):e59313. https:\/\/doi.org\/10.1371\/journal.pone.0059313","journal-title":"PLoS One"},{"issue":"9548","key":"2283_CR143","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368(9548):1696\u20131705. https:\/\/doi.org\/10.1016\/S0140-6736(06)69705-5","journal-title":"Lancet"},{"issue":"10","key":"2283_CR144","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.molmet.2015.07.008","volume":"4","author":"SC Cork","year":"2015","unstructured":"Cork SC, Richards JE, Holt MK, Gribble FM, Reimann F, Trapp S (2015) Distribution and characterisation of glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol Metab 4(10):718\u2013731. https:\/\/doi.org\/10.1016\/j.molmet.2015.07.008","journal-title":"Mol Metab"},{"issue":"6","key":"2283_CR145","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/jnc.12036","volume":"123","author":"K Velmurugan","year":"2012","unstructured":"Velmurugan K, Bouchard R, Mahaffey G, Pugazhenthi S (2012) Neuroprotective actions of glucagon-like peptide-1 in differentiated human neuroprogenitor cells. J Neurochem 123(6):919\u2013931. https:\/\/doi.org\/10.1111\/jnc.12036","journal-title":"J Neurochem"},{"issue":"1","key":"2283_CR146","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.bbr.2009.06.035","volume":"205","author":"T Abbas","year":"2009","unstructured":"Abbas T, Faivre E, Holscher C (2009) Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer\u2019s disease. Behav Brain Res 205(1):265\u2013271. https:\/\/doi.org\/10.1016\/j.bbr.2009.06.035","journal-title":"Behav Brain Res"},{"issue":"4","key":"2283_CR147","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3233\/JAD-2010-1314","volume":"19","author":"Y Li","year":"2010","unstructured":"Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW, Tweedie D, Perry T et al (2010) GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer\u2019s disease. J Alzheimers Dis 19(4):1205\u20131219. https:\/\/doi.org\/10.3233\/JAD-2010-1314","journal-title":"J Alzheimers Dis"},{"key":"2283_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2019.111932","volume":"370","author":"J An","year":"2019","unstructured":"An J, Zhou Y, Zhang M, Xie Y, Ke S, Liu L, Pan X, Chen Z (2019) Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5xFAD mouse model of Alzheimer\u2019s disease. Behav Brain Res 370:111932. https:\/\/doi.org\/10.1016\/j.bbr.2019.111932","journal-title":"Behav Brain Res"},{"issue":"1","key":"2283_CR149","doi-asserted-by":"publisher","DOI":"10.1186\/s12868-016-0272-9","volume":"17","author":"PC Li","year":"2016","unstructured":"Li PC, Liu LF, Jou MJ, Wang HK (2016) The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice. BMC Neurosci 17(1):37. https:\/\/doi.org\/10.1186\/s12868-016-0272-9","journal-title":"BMC Neurosci"},{"issue":"1","key":"2283_CR150","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-03792-9","volume":"7","author":"L Rachmany","year":"2017","unstructured":"Rachmany L, Tweedie D, Rubovitch V, Li Y, Holloway HW, Kim DS, Ratliff WA, Saykally JN et al (2017) Exendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in vitro TBI-induced hippocampal cellular degeneration. Sci Rep 7(1):3735. https:\/\/doi.org\/10.1038\/s41598-017-03792-9","journal-title":"Sci Rep"},{"issue":"12","key":"2283_CR151","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082016","volume":"8","author":"K Eakin","year":"2013","unstructured":"Eakin K, Li Y, Chiang YH, Hoffer BJ, Rosenheim H, Greig NH, Miller JP (2013) Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. PLoS One 8(12):e82016. https:\/\/doi.org\/10.1371\/journal.pone.0082016","journal-title":"PLoS One"},{"issue":"8","key":"2283_CR152","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/ijo.2010.59","volume":"34","author":"VA Gault","year":"2010","unstructured":"Gault VA, Porter WD, Flatt PR, Holscher C (2010) Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet. Int J Obes 34(8):1341\u20131344. https:\/\/doi.org\/10.1038\/ijo.2010.59","journal-title":"Int J Obes"},{"key":"2283_CR153","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.neurobiolaging.2017.12.009","volume":"64","author":"M Bomba","year":"2018","unstructured":"Bomba M, Granzotto A, Castelli V, Massetti N, Silvestri E, Canzoniero LMT, Cimini A, Sensi SL (2018) Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice. Neurobiol Aging 64:33\u201343. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2017.12.009","journal-title":"Neurobiol Aging"},{"issue":"6","key":"2283_CR154","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/s41366-020-0535-5","volume":"44","author":"F Vadini","year":"2020","unstructured":"Vadini F, Simeone PG, Boccatonda A, Guagnano MT, Liani R, Tripaldi R, Di Castelnuovo A, Cipollone F et al (2020) Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. Int J Obes 44(6):1254\u20131263. https:\/\/doi.org\/10.1038\/s41366-020-0535-5","journal-title":"Int J Obes"},{"issue":"7","key":"2283_CR155","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.2337\/dc18-2584","volume":"42","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Zhang B, Wang X, Zhang X, Yang QX, Qing Z, Zhang W, Zhu D et al (2019) Olfactory dysfunction mediates adiposity in cognitive impairment of type 2 diabetes: insights from clinical and functional neuroimaging studies. Diabetes Care 42(7):1274\u20131283. https:\/\/doi.org\/10.2337\/dc18-2584","journal-title":"Diabetes Care"},{"key":"2283_CR156","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.bbr.2018.08.006","volume":"356","author":"KT Watson","year":"2019","unstructured":"Watson KT, Wroolie TE, Tong G, Foland-Ross LC, Frangou S, Singh M, McIntyre RS, Roat-Shumway S et al (2019) Neural correlates of liraglutide effects in persons at risk for Alzheimer\u2019s disease. Behav Brain Res 356:271\u2013278. https:\/\/doi.org\/10.1016\/j.bbr.2018.08.006","journal-title":"Behav Brain Res"},{"key":"2283_CR157","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","volume":"8","author":"M Gejl","year":"2016","unstructured":"Gejl M, Gjedde A, Egefjord L, Moller A, Hansen SB, Vang K, Rodell A, Braendgaard H et al (2016) In Alzheimer\u2019s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci 8:108. https:\/\/doi.org\/10.3389\/fnagi.2016.00108","journal-title":"Front Aging Neurosci"},{"key":"2283_CR158","doi-asserted-by":"publisher","unstructured":"Duarte AI, Candeias E, Alves IN, Mena D, Silva DF, Machado NJ, Campos EJ, Santos MS et al (2020) Liraglutide protects against brain amyloid-beta1-42 accumulation in female mice with early Alzheimer\u2019s disease-like pathology by partially rescuing oxidative\/nitrosative stress and inflammation. Int J Mol Sci 21(5). https:\/\/doi.org\/10.3390\/ijms21051746","DOI":"10.3390\/ijms21051746"},{"issue":"17","key":"2283_CR159","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","volume":"31","author":"PL McClean","year":"2011","unstructured":"McClean PL, Parthsarathy V, Faivre E, Holscher C (2011) The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease. J Neurosci 31(17):6587\u20136594. https:\/\/doi.org\/10.1523\/JNEUROSCI.0529-11.2011","journal-title":"J Neurosci"},{"key":"2283_CR160","doi-asserted-by":"publisher","unstructured":"McClean PL, Holscher C (2014) Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP\/PS1 mice, a model of Alzheimer\u2019s disease. Neuropharmacology 76 Pt A:57\u201367. https:\/\/doi.org\/10.1016\/j.neuropharm.2013.08.005","DOI":"10.1016\/j.neuropharm.2013.08.005"},{"issue":"1","key":"2283_CR161","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/path.5056","volume":"245","author":"AF Batista","year":"2018","unstructured":"Batista AF, Forny-Germano L, Clarke JR, Lyra ESNM, Brito-Moreira J, Boehnke SE, Winterborn A, Coe BC et al (2018) The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer\u2019s disease. J Pathol 245(1):85\u2013100. https:\/\/doi.org\/10.1002\/path.5056","journal-title":"J Pathol"},{"issue":"7","key":"2283_CR162","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158205","volume":"11","author":"HH Hansen","year":"2016","unstructured":"Hansen HH, Fabricius K, Barkholt P, Kongsbak-Wismann P, Schlumberger C, Jelsing J, Terwel D, Termont A et al (2016) Long-term treatment with liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has no effect on beta-amyloid plaque load in two transgenic APP\/PS1 mouse models of Alzheimer\u2019s disease. PLoS One 11(7):e0158205. https:\/\/doi.org\/10.1371\/journal.pone.0158205","journal-title":"PLoS One"},{"issue":"10","key":"2283_CR163","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/j.1463-1326.2010.01259.x","volume":"12","author":"DW Porter","year":"2010","unstructured":"Porter DW, Kerr BD, Flatt PR, Holscher C, Gault VA (2010) Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. Diabetes Obes Metab 12(10):891\u2013899. https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01259.x","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2283_CR164","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/ijo.2012.91","volume":"37","author":"WD Porter","year":"2013","unstructured":"Porter WD, Flatt PR, Holscher C, Gault VA (2013) Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob\/ob mice. Int J Obes 37(5):678\u2013684. https:\/\/doi.org\/10.1038\/ijo.2012.91","journal-title":"Int J Obes"},{"issue":"7","key":"2283_CR165","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S1474-4422(20)30173-3","volume":"19","author":"T Cukierman-Yaffe","year":"2020","unstructured":"Cukierman-Yaffe T, Gerstein HC, Colhoun HM, Diaz R, Garcia-Perez LE, Lakshmanan M, Bethel A, Xavier D et al (2020) Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol 19(7):582\u2013590. https:\/\/doi.org\/10.1016\/S1474-4422(20)30173-3","journal-title":"Lancet Neurol"},{"issue":"1","key":"2283_CR166","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.bbrc.2017.11.114","volume":"495","author":"HY Cai","year":"2018","unstructured":"Cai HY, Yang JT, Wang ZJ, Zhang J, Yang W, Wu MN, Qi JS (2018) Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP\/PS1\/tau mouse model of Alzheimer\u2019s disease. Biochem Biophys Res Commun 495(1):1034\u20131040. https:\/\/doi.org\/10.1016\/j.bbrc.2017.11.114","journal-title":"Biochem Biophys Res Commun"},{"key":"2283_CR167","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.neuropharm.2014.07.015","volume":"86","author":"PL McClean","year":"2014","unstructured":"McClean PL, Holscher C (2014) Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer\u2019s disease. Neuropharmacology 86:241\u2013258. https:\/\/doi.org\/10.1016\/j.neuropharm.2014.07.015","journal-title":"Neuropharmacology"},{"key":"2283_CR168","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.peptides.2014.08.014","volume":"61","author":"R Lennox","year":"2014","unstructured":"Lennox R, Flatt PR, Gault VA (2014) Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice. Peptides 61:38\u201347. https:\/\/doi.org\/10.1016\/j.peptides.2014.08.014","journal-title":"Peptides"},{"issue":"4","key":"2283_CR169","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/13543784.2020.1738383","volume":"29","author":"C Holscher","year":"2020","unstructured":"Holscher C (2020) Brain insulin resistance: role in neurodegenerative disease and potential for targeting. Expert Opin Investig Drugs 29(4):333\u2013348. https:\/\/doi.org\/10.1080\/13543784.2020.1738383","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"2283_CR170","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1505","volume":"10","author":"C Li","year":"2020","unstructured":"Li C, Liu W, Li X, Zhang Z, Qi H, Liu S, Yan N, Xing Y et al (2020) The novel GLP-1\/GIP analogue DA5-CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD. Brain Behav 10(3):e01505. https:\/\/doi.org\/10.1002\/brb3.1505","journal-title":"Brain Behav"},{"key":"2283_CR171","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ejphar.2018.03.024","volume":"827","author":"Y Cao","year":"2018","unstructured":"Cao Y, Holscher C, Hu MM, Wang T, Zhao F, Bai Y, Zhang J, Wu MN et al (2018) DA5-CH, a novel GLP-1\/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP\/PS1 mouse model of Alzheimer\u2019s disease. Eur J Pharmacol 827:215\u2013226. https:\/\/doi.org\/10.1016\/j.ejphar.2018.03.024","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"2283_CR172","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hipo.22837","volume":"28","author":"T Li","year":"2018","unstructured":"Li T, Jiao JJ, Holscher C, Wu MN, Zhang J, Tong JQ, Dong XF, Qu XS et al (2018) A novel GLP-1\/GIP\/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer\u2019s disease. Hippocampus 28(5):358\u2013372. https:\/\/doi.org\/10.1002\/hipo.22837","journal-title":"Hippocampus"},{"key":"2283_CR173","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.brainres.2017.10.012","volume":"1678","author":"J Tai","year":"2018","unstructured":"Tai J, Liu W, Li Y, Li L, Holscher C (2018) Neuroprotective effects of a triple GLP-1\/GIP\/glucagon receptor agonist in the APP\/PS1 transgenic mouse model of Alzheimer\u2019s disease. Brain Res 1678:64\u201374. https:\/\/doi.org\/10.1016\/j.brainres.2017.10.012","journal-title":"Brain Res"},{"key":"2283_CR174","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154265","volume":"109","author":"JB Zhou","year":"2020","unstructured":"Zhou JB, Tang X, Han M, Yang J, Simo R (2020) Impact of antidiabetic agents on dementia risk: a Bayesian network meta-analysis. Metabolism 109:154265. https:\/\/doi.org\/10.1016\/j.metabol.2020.154265","journal-title":"Metabolism"},{"key":"2283_CR175","doi-asserted-by":"publisher","unstructured":"Chen KC, Chung CH, Lu CH, Tzeng NS, Lee CH, Su SC, Kuo FC, Liu JS et al (2020) Association between the use of dipeptidyl peptidase 4 inhibitors and the risk of dementia among patients with type 2 diabetes in Taiwan. J Clin Med 9(3). https:\/\/doi.org\/10.3390\/jcm9030660","DOI":"10.3390\/jcm9030660"},{"key":"2283_CR176","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.diabres.2016.12.010","volume":"123","author":"AT Isik","year":"2017","unstructured":"Isik AT, Soysal P, Yay A, Usarel C (2017) The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer\u2019s disease. Diabetes Res Clin Pract 123:192\u2013198. https:\/\/doi.org\/10.1016\/j.diabres.2016.12.010","journal-title":"Diabetes Res Clin Pract"},{"key":"2283_CR177","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.neulet.2018.12.041","volume":"696","author":"Q Dong","year":"2019","unstructured":"Dong Q, Teng SW, Wang Y, Qin F, Li Y, Ai LL, Yu H (2019) Sitagliptin protects the cognition function of the Alzheimer\u2019s disease mice through activating glucagon-like peptide-1 and BDNF-TrkB signalings. Neurosci Lett 696:184\u2013190. https:\/\/doi.org\/10.1016\/j.neulet.2018.12.041","journal-title":"Neurosci Lett"},{"issue":"4","key":"2283_CR178","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/dom.12432","volume":"17","author":"VA Gault","year":"2015","unstructured":"Gault VA, Lennox R, Flatt PR (2015) Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline. Diabetes Obes Metab 17(4):403\u2013413. https:\/\/doi.org\/10.1111\/dom.12432","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2283_CR179","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/JOE-12-0521","volume":"218","author":"H Pintana","year":"2013","unstructured":"Pintana H, Apaijai N, Chattipakorn N, Chattipakorn SC (2013) DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats. J Endocrinol 218(1):1\u201311. https:\/\/doi.org\/10.1530\/JOE-12-0521","journal-title":"J Endocrinol"},{"issue":"5","key":"2283_CR180","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1097\/HJH.0000000000000529","volume":"33","author":"TH Tsai","year":"2015","unstructured":"Tsai TH, Sun CK, Su CH, Sung PH, Chua S, Zhen YY, Leu S, Chang HW et al (2015) Sitagliptin attenuated brain damage and cognitive impairment in mice with chronic cerebral hypo-perfusion through suppressing oxidative stress and inflammatory reaction. J Hypertens 33(5):1001\u20131013. https:\/\/doi.org\/10.1097\/HJH.0000000000000529","journal-title":"J Hypertens"},{"key":"2283_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2020.104013","volume":"88","author":"E Ates Bulut","year":"2020","unstructured":"Ates Bulut E, Sahin Alak ZY, Dokuzlar O, Kocyigit SE, Soysal P, Smith L, Isik AT (2020) Cognitive and metabolic outcomes of vildagliptin addition to the therapy in patients with type 2 diabetes mellitus: 26 week follow-up study. Arch Gerontol Geriatr 88:104013. https:\/\/doi.org\/10.1016\/j.archger.2020.104013","journal-title":"Arch Gerontol Geriatr"},{"issue":"9","key":"2283_CR182","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1093\/gerona\/glu032","volume":"69","author":"MR Rizzo","year":"2014","unstructured":"Rizzo MR, Barbieri M, Boccardi V, Angellotti E, Marfella R, Paolisso G (2014) Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment. J Gerontol A Biol Sci Med Sci 69(9):1122\u20131131. https:\/\/doi.org\/10.1093\/gerona\/glu032","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2283_CR183","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2019.06.001","volume":"84","author":"AM Borzi","year":"2019","unstructured":"Borzi AM, Condorelli G, Biondi A, Basile F, Vicari ESD, Buscemi C, Luca S, Vacante M (2019) Effects of vildagliptin, a DPP-4 inhibitor, in elderly diabetic patients with mild cognitive impairment. Arch Gerontol Geriatr 84:103896. https:\/\/doi.org\/10.1016\/j.archger.2019.06.001","journal-title":"Arch Gerontol Geriatr"},{"issue":"7","key":"2283_CR184","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.arcmed.2014.09.002","volume":"45","author":"J Sripetchwandee","year":"2014","unstructured":"Sripetchwandee J, Pipatpiboon N, Pratchayasakul W, Chattipakorn N, Chattipakorn SC (2014) DPP-4 inhibitor and PPARgamma agonist restore the loss of CA1 dendritic spines in obese insulin-resistant rats. Arch Med Res 45(7):547\u2013552. https:\/\/doi.org\/10.1016\/j.arcmed.2014.09.002","journal-title":"Arch Med Res"},{"issue":"5","key":"2283_CR185","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/ejn.12088","volume":"37","author":"N Pipatpiboon","year":"2013","unstructured":"Pipatpiboon N, Pintana H, Pratchayasakul W, Chattipakorn N, Chattipakorn SC (2013) DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption. Eur J Neurosci 37(5):839\u2013849. https:\/\/doi.org\/10.1111\/ejn.12088","journal-title":"Eur J Neurosci"},{"key":"2283_CR186","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ejphar.2015.11.033","volume":"769","author":"MM El Batsh","year":"2015","unstructured":"El Batsh MM, El Batch MM, Shafik NM, Younos IH (2015) Favorable effects of vildagliptin on metabolic and cognitive dysfunctions in streptozotocin-induced diabetic rats. Eur J Pharmacol 769:297\u2013305. https:\/\/doi.org\/10.1016\/j.ejphar.2015.11.033","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"2283_CR187","doi-asserted-by":"publisher","first-page":"5100","DOI":"10.3892\/etm.2018.6016","volume":"15","author":"DD Zhang","year":"2018","unstructured":"Zhang DD, Shi N, Fang H, Ma L, Wu WP, Zhang YZ, Tian JL, Tian LB et al (2018) Vildagliptin, a DPP4 inhibitor, alleviates diabetes-associated cognitive deficits by decreasing the levels of apoptosis-related proteins in the rat hippocampus. Exp Ther Med 15(6):5100\u20135106. https:\/\/doi.org\/10.3892\/etm.2018.6016","journal-title":"Exp Ther Med"},{"key":"2283_CR188","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejphar.2015.02.024","volume":"755","author":"S Pugazhenthi","year":"2015","unstructured":"Pugazhenthi S, Qin L, Bouchard R (2015) Dipeptidyl peptidase-4 inhibition in diabetic rats leads to activation of the transcription factor CREB in beta-cells. Eur J Pharmacol 755:42\u201349. https:\/\/doi.org\/10.1016\/j.ejphar.2015.02.024","journal-title":"Eur J Pharmacol"},{"key":"2283_CR189","doi-asserted-by":"publisher","unstructured":"Biessels GJ, Verhagen C, Janssen J, van den Berg E, Zinman B, Rosenstock J, George JT, Passera A et al (2019) Effect of linagliptin on cognitive performance in patients with type 2 diabetes and cardiorenal comorbidities: the CARMELINA randomized trial. Diabetes Care 42(10) 1930-1938. https:\/\/doi.org\/10.2337\/dc19-0783","DOI":"10.2337\/dc19-0783"},{"issue":"8","key":"2283_CR190","doi-asserted-by":"publisher","first-page":"6074","DOI":"10.1007\/s12035-016-0125-7","volume":"54","author":"J Kosaraju","year":"2017","unstructured":"Kosaraju J, Holsinger RMD, Guo L, Tam KY (2017) Linagliptin, a dipeptidyl peptidase-4 inhibitor, mitigates cognitive deficits and pathology in the 3xTg-AD mouse model of Alzheimer\u2019s disease. Mol Neurobiol 54(8):6074\u20136084. https:\/\/doi.org\/10.1007\/s12035-016-0125-7","journal-title":"Mol Neurobiol"},{"issue":"3","key":"2283_CR191","doi-asserted-by":"publisher","first-page":"R466","DOI":"10.1152\/ajpregu.00057.2016","volume":"311","author":"T Hardigan","year":"2016","unstructured":"Hardigan T, Yasir A, Abdelsaid M, Coucha M, El-Shaffey S, Li W, Johnson MH, Ergul A (2016) Linagliptin treatment improves cerebrovascular function and remodeling and restores reduced cerebral perfusion in type 2 diabetes. Am J Physiol Regul Integr Comp Physiol 311(3):R466\u2013R477. https:\/\/doi.org\/10.1152\/ajpregu.00057.2016","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2283_CR192","doi-asserted-by":"publisher","unstructured":"Nakaoku Y, Saito S, Yamamoto Y, Maki T, Takahashi R, Ihara M (2019) The dipeptidyl Peptidase-4 inhibitor linagliptin ameliorates high-fat induced cognitive decline in Tauopathy model mice. Int J Mol Sci 20(10). https:\/\/doi.org\/10.3390\/ijms20102539","DOI":"10.3390\/ijms20102539"},{"key":"2283_CR193","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12933-015-0218-z","volume":"14","author":"M Ma","year":"2015","unstructured":"Ma M, Hasegawa Y, Koibuchi N, Toyama K, Uekawa K, Nakagawa T, Lin B, Kim-Mitsuyama S (2015) DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice. Cardiovasc Diabetol 14:54. https:\/\/doi.org\/10.1186\/s12933-015-0218-z","journal-title":"Cardiovasc Diabetol"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-021-02283-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-021-02283-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-021-02283-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T12:28:19Z","timestamp":1621254499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-021-02283-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,23]]},"references-count":193,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["2283"],"URL":"https:\/\/doi.org\/10.1007\/s12035-021-02283-3","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,23]]},"assertion":[{"value":"14 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The authors give consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}